A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 140
- Population
- ALL · 70 Years to 85 Years
- Duration
- 2024-03-01 to 2028-12-31
- Intervention
- S-1; Toripalimab; Intensity-modulated radiotherapy
- Comparator
- The control group
- Outcomes measured
- Progression-free survival — From date of enrollment until the date of death from any cause or the date of first documen…; Overall survival — From date of enrollment until the date of death from any cause or the date of last follow-up, whiche…; Clinical complete response — 13-16 weeks after the completion of radiotherapy; Duration of response — From date of first CR/PR to the date of first PD according to RECIST criteria, assessed up to 36…; Treatment-related adverse events — From date of enrollment to the date of last follow-up, assessed up to 36 months.
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.